Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.
Bile reflux has been implicated in the pathogenesis and malignant degeneration of Barrett's esophagus, but clinical studies in patients with adenocarcinoma arising in Barrett's esophagus are lacking. Ambulatory esophageal measurement of acid and bile reflux was performed with the previously validated fiberoptic bilirubin monitoring system (Bilitec) combined with a pH probe in 20 asymptomatic volunteers, 19 patients with gastroesophageal reflux disease (GERD) but no mucosal injury, 45 patients with GERD and erosive esophagitis, 33 patients with GERD and Barrett's esophagus, and 14 patients with early adenocarcinoma arising in Barrett's esophagus. Repeat studies were done in 15 patients under medical acid suppression and 16 patients after laparoscopic Nissen fundoplication. The mean esophageal bile exposure time showed an exponential increase from GERD patients without esophagitis to those with erosive esophagitis and benign Barrett's esophagus and was highest in patients with early carcinoma in Barrett's esophagus (P <0.01). Pathologic esophageal bile exposure was documented in 18 (54.5%) of 33 patients with benign Barrett's esophagus and 11 (78.6%) of 14 patients with early adenocarcinoma in Barrett's esophagus. Nissen fundoplication but not medical acid suppression resulted in complete suppression of bile reflux. Bile reflux into the esophagus is particularly prevalent in patients with Barrett's esophagus and early cancer. Bile reflux into the esophagus can be completely suppressed by Nissen fundoplication but not medical acid suppression alone.
Stein
H J
HJ
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU München, München, Germany.
Kauer
W K
WK
Feussner
H
H
Siewert
J R
JR
D000230:Adenocarcinoma / Q000150:complications / Q000503:physiopathology; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000150:complications* / Q000503:physiopathology; D001646:Bile / Q000737:chemistry; D001655:Bile Reflux / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control; D001663:Bilirubin / Q000032:analysis; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000150:complications / Q000503:physiopathology; D004942:Esophagitis, Peptic / Q000150:complications / Q000503:physiopathology; D004947:Esophagus / Q000503:physiopathology; D005260:Female; D005336:Fiber Optic Technology / Q000295:instrumentation; D018662:Fundoplication; D005744:Gastric Acid / Q000737:chemistry; D005764:Gastroesophageal Reflux / Q000150:complications / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D018670:Monitoring, Ambulatory; D009853:Omeprazole / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors
D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D001663:Bilirubin